Company intelligence / Profile preview

Huimei Technology

Beijing, Beijing Shi, Chinapitchbook.com ↗

Ownership: Private
Development stage: Commercial

Overview

Huimei Technology develops and commercializes artificial intelligence solutions for healthcare providers. Its core product, Dr. Mayson CDSS, assists clinicians in real-time decision-making to improve diagnostic accuracy and clinical quality using natural language processing and deep learning techniques. The company’s products are deployed in hospitals to enhance patient care but do not themselves undergo traditional drug development stages.

Therapeutic areas: Other
Modalities: Non-pharmacological therapy (AI-powered clinical decision support and diagnostics)
Industry: Digital Health Medical Devices

Partnerships

Not specified in available sources.

Beyond the preview

Go deeper on Huimei Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huimei Technology.

Explore the full profile